NCT06223607
Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
Recruiting
Not specifiedAges 18+ObservationalMethodist Health SystemInvestigator-initiated
~300 participants
Updated 2026-06-10 on ClinicalTrials.gov
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of bleeding
Measured over 1 year
Conditions
NCT06223607
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Methodist Dallas Medical Center
Dallas, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jessica Rago Crotty, Pharm D · PRINCIPAL_INVESTIGATOR · Methodist Midlothian Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
≥ 18 years
PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
Exclusion
Death within 48 hours post-PCI
DAPT prior to cardiac catheterization
What this trial measures
- Incidence of bleeding1 year
To evaluate the difference in bleeding rates in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.